


References




A

Alan McNeil. The Trouble with troponin . *Heart, Lung and Circulation*, **2007**; 16(3):S13-S16

Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined—a consensus document of the joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. *J Am Coll Cardiol* **2000**;36:959.

Angelika Hammerer-Lercher, Petra Erlacher, Reginald Bittner, et al. Clinical and Experimental Results on Cardiac Troponin Expression in Duchenne Muscular Dystrophy; *Clin. Chem.* **2001**; 47: 451-458.




B

Benedetti S, Merlini L. Laminopathies: from the heart of the cell to the clinics. *Curr Opin Neurol* **2004**;17:553–60.


Beynon RP, Ray SG. Cardiac involvement in muscular dystrophies. *Qjm* **2008**; 101: 337–344.

Bhagat CI, Langton P, Lewer M, et al. Cardiac Troponin I should replace CK MB for the diagnosis of acute myocardial infarction. *Clin Biochem* **1997**;34:511–6.

- Biddison JH, Dembo DH, Spalt H, et al.** Familial occurrence of mitral valve prolapse in X-linked muscular dystrophy. *Circulation* **1979**;59(6):1299-1304.
- Biggar WD, Gingras M, Fehlings DL, et al.** Deflazacort treatment of Duchennemuscular dystrophy. *J Pediatr.* **2001**;138 :45 –50.
- Bodor GS, Posterfield D, Voss EM, et al.** Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. *Clin Chem* **1995**;41:1710–5.
- Bonne G, Leturcq F, Récan-Budiartha D, et al.** Emery–Dreifuss muscular dystrophy. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. www.genetests.org **2007**.
- Bulkley BH, Roberts WC.** The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. *Am J Med.* **1975**;58 :243 –264
- Bushby KM, Goodship JA, Nicholson LV, et al.** Variability in clinical, genetic and protein abnormalities in manifesting carriers of Duchenne and Becker muscular dystrophy. *Neuromuscul Disord* **1993**;3(1):57-64.
- Bushby K, Muntoni F, Bourke JP.** 107th ENMC International Workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy—7th–9th. Naarden, the Netherlands. *Neuromuscul Disord.* **2003**;13 :166 –172.
-



- Carole Vuillerot, Franoise Girardot, Christine Payan, et al.** Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure, *Developmental medicine and child neurology* **2010**; 52: 60–65D.
- Castro-Gago M, Gomez-Lado C and Jesus Eirs-Pun AL.** Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients. *Brain & Development*, **2009**; 31: 184
- Chenard AA, Becane HM, Tertrain F, et al.** Ventricular arrhythmia in Duchenne muscular dystrophy: prevalence, significance and prognosis. *Neuromuscul Disord.* **1993**;3:201 – 206.
- Comi LI, Nigro G, Politano L, et al.** The cardiomyopathy of Duchenne/Becker consultands. *Int J Cardiol* **1992**;34(3):297-305.
- Connuck DM, Sleeper LA, Colan SD et al.** Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. *Am Heart J* **2008**; 155: 998–1005.
-



Daphne T. Cardiac manifestations of neuromuscular disorders in children. *Paediatric Respiratory Reviews* **2010**; 11(1): 35-38.

de Kermadec JM, Becane HM, Chenard A, et al. Prevalence of left ventricular systolic dysfunction in Duchenne muscular dystrophy: an echocardiographic study. *Am Heart J*. **1994**;127 :618 –623.

Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. *N Engl J Med* **1994**;331(23):1564-1575.

Dellefave L, McNally E. Cardiomyopathy in neuromuscular disorders. *Prog Ped Card* **2007**; 24: 35–46.


Dent KM, Dunn DM, von Niederhausern AC, et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. *Am J Med Genet A*. **2005**;134 (3):295 –298.

Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. *J Am Coll Cardiol* **2005**; 45: 855–857.

Duboc D, Meune C, Pierre B, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' followup. *Am Heart J* **2007**; 154: 596–602.

Dubowitz V. 75th European Neuromuscular Centre International Workshop: 2nd workshop on the treatment of muscular dystrophy 10–12 December, 1999, Naarden, the Netherlands. *Neuromuscul Disord.* **2000**;10 :313–320

Dubrovsky AL, Angelini C, Bonifati MD, et al. Steroids in muscular dystrophy: where do we stand? *Neuromuscul Disord.* **1998**;8 :380–384.



Eagle M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. *Neuromuscul Disord.* **2002**;12 :926–929

Emery AE. Population frequencies of inherited neuromuscular diseases: a world survey. *Neuromuscul Disord.* **1991**;1 :19–29

Emery AE. The muscular dystrophies. *Lancet* **2002**;359:687–695.

Emery AEH. Abnormalities of the electrocardiogram in female carriers of Duchenne muscular dystrophy. *Br Med J* **1969**;2:418-420.

English KM, Gibbs JL. Cardiac monitoring and treatment for children and adolescents with neuromuscular disorders. *Dev Med Child Neurol* **2006**; 48: 231–235.

F

Ferlini A, Sewry C, Melis MA, et al. X-linked dilated cardiomyopathy and the dystrophin gene. *Neuromuscul Disord* **1999**; 9: 339–346.

Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. *Am J Respir Crit Care Med*. **2004**;170:456-465

Finsterer J, Stollberger C. The heart in human dystrophinopathies. *Cardiology* **2003**;99:1–19.


Finsterer J. Cardiogenetics, neurogenetics, and pathogenetics of left ventricular hypertrabeculation/noncompaction. *Pediatr Cardiol* **2009**; 30: 659–681.

G

Giglio V, Pasceri V, Messano L, et al. Ultrasound tissue characterization detects preclinical myocardial structural changes in children affected by Duchenne muscular dystrophy. *J Am Coll Cardiol*. **2003**;42 :309 –316.

Goldfarb LG, Dalakas MC. Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. *J Clin Invest* **2009**;119:1806–13.

Gulati Shefalli Anita Saxena¹, Virender Kumar et al. Duchenne Muscular Dystrophy: Prevalence and Patterns of Cardiac Involvement. *Journal of Pediatrics* **2004**; 72.



- Harper PS.** Myotonic dystrophy. London: Saunders; **2001**.
- Henderson , A.R ,Donald . W.M.** Enzymes , Tietz fundamentals of clinical chemistry .5th edition .,Burtis , C.A & Ashwood, E.R(W.B. Saunders eds. Philadelphia USA) (**2001**), 352.
- Hermans MC, Faber CG, Pinto YM.** Sudden death in myotonic dystrophy. *N Engl J Med* **2008**;359:1626–8.
- Hermans MC, Pinto YM, Merkies IS, et al.** Hereditary muscular dystrophies and the heart. *Neuromuscul Disord* **2010**; 20: 479-49.
- Hoffman EP, Brown RH, Kunkel LM.** Dystrophin: the protein product of the Duchene muscular dystrophy locus. 1987. *Biotechnology*. **1992**;24 :457 –466
- Holaska JM.** Emerin and the nuclear lamina in muscle and cardiac disease. *Circ Res* **2008**; 103: 16–23.
- Hoogerwaard E.M., van der Wouw P.A., Wilde A.A.M., et al.,.** Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. *Neuromuscular Disorders* **1999**;9: 347-351
- Hoogerwaard EM, Voogt WG, de Wilde AAM, et al.** Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. *J Neurol* **1997**;244:657-663
-

- Hor KN, Wansapura J, Markham LW et al.** Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study. *J Am Coll Cardiol* **2009**; 53: 1204–1210.
- Horwich T.B., Patel J., MacLellan W.R., et al.** Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure, *Circulation* **2003**;108: 833–838.
- Hsiao J.-F., Ning H.-C., Gu P.-W., et al.** Clinical role of recurrently elevated macro creatine kinase type 1. *Journal of Clinical Laboratory Analysis* **2008**; 22: 186–191.
- Hsu DT.** Cardiac manifestations of neuromuscular disorders in children. *Paediatric Respiratory Reviews* **2009**;11: 35-38
- Hunt SA.** ACC/AHA guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *J Am Coll Cardiol* **2005**; 46: e1–82.
-

I

Ishikawa K. Cardiac involvement in progressive muscular dystrophy of the Duchenne type. *Jpn Heart J* **1997**; 38: 163–180.

Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. *Am Heart J.* **1999**;137: 895 –902.

J

Janet Kay Bobo, Aileen Kenneson, Katherine Kolor, et al. Adherence to American Academy of Pediatrics Recommendations for Cardiac Care Among Female Carriers of Duchenne and Becker Muscular Dystrophy. *Pediatrics* **2009**,3: e471-e475.

Jefferies JL, Eidem BW, Belmont JW et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. *Circulation* **2005**; 112: 2799–2804.

K

Katus HA. Development of the cardiac troponin T immunoassay, *Clzn. Chem.* **2008**;54: 1576–1577.

Kichuk Chrisant MR, Drummond-Webb J, Hallowell S, et al.

Cardiac transplantation in twins with autosomal dominant Emery-Dreifuss muscular dystrophy. *J Heart Lung Transplant* **2004**; 23: 496–498.

Kirchmann C, Kececioglu D, Korinthenberg R, et al.


Echocardiographic and electrocardiographic findings of cardiomyopathy in Duchenne and Becker-Kiener muscular dystrophies. *Pediatr Cardiol* **2005**; 26: 66–72.

Klitzner TS, Beekman RH, Galioto FM, et al. Cardiovascular

health supervision for individuals affected by Duchenne or Becker muscular dystrophy. *Pediatrics* **2005**; 116:1569–73.

Kunkel LM, Monaco AP, Middlesworth W, et al. Specific cloning

of DNA fragments absent from the DNA of a male patient with an X chromosome deletion. *Proc Natl Acad Sci USA*. **1985**;82:4778–4782.



La L.V., Mezzena G., Zanolla L. et al. Cardiac troponin I as

diagnostic and prognostic marker in severe heart failure, *J. Heart Lung Transplant*. **2000**;19: 644–652.

Lane RJM, Gardner-Medwin D, Roses AD. Electrocardiographic


abnormalities in carriers of Duchenne muscular dystrophy. *Neurology* **1980**;30:497-501.

Lanza GA, Dello Russo A, Giglio V, et al. Impairment of cardiac autonomic function in patients with Duchenne muscular dystrophy: relationship to myocardial and respiratory function. *Am Heart J* **2001**;141 :808–812

Laval SH, Bushby KM. Limb-girdle muscular dystrophies – from genetics to molecular pathology. *Neuropathol Appl Neurobiol* **2004**;30:91–105.

Lin JC, Apple FS, Murakami MM, et al. Rates of positive cardiac Troponin I and creatine kinase MB mass among patients hospitalised for suspected acute coronary syndromes. *Clin Chem* **2004**;50:333–8.

Lunt PW. 44th ENMC International Workshop: Facioscapulohumeral Muscular Dystrophy: Molecular Studies 19–21 July 1996, Naarden, The Netherlands. *Neuromuscul Disord* **1998**;8:126–30.




Manzur AY, Muntoni F. Diagnosis and new treatments in muscular dystrophies. *J Neurol Neurosurg Psychiatry* **2009**; 80: 706–714.

Martins E, Silva-Cardoso J, Silveira F, et al. Left ventricular function in adults with muscular dystrophies: genotype-phenotype correlations. *Rev Port Cardiol* **2005**; 24: 23–35.

- Matsumura T, Saito T, Fujimura H, et al.** Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients. *Brain Dev* **2007**;29:496–501.
- Matsumura T, Saito T, Fujimura, et al.** Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients; *Brain & Development* **2007**; 29: 496–501.
- McNally EM,T Towbin JA.** Cardiomyopathy in Muscular Dystrophy Workshop 28–30 September 2003, Tucson, Arizona. *Neuromuscular Disorders* **2004**;14: 442–448
- Melacini P, Fanin M, Danieli GA, et al.** Myocardial involvement is very frequent among patients affected with subclinical Becker’s muscular dystrophy. *Circulation* **1996**; 94: 3168–3175.
- Mendell JR, Buzin CH, Feng J, et al.** Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. *Neurology*. **2001**;57 (4):645 –650.
- Mesa LE, Dubrovsky AL, Corderi J, et al.** Steroids in Duchenne muscular dystrophy: deflazacort trial. *Neuromuscul Disord*. **1991**;1 :261 –266.
- Mirabella M, Servidei S, Manfredi G, et al.** Cardiomyopathy may be the only clinical manifestation in female carriers of Duchenne muscular dystrophy. *Neurology* **1993**;43:2342-2345.
- Monaco AP, Bertelson CJ, Liechti-Gallati S, et al.** An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. *Genomics*. **1988**;2 :90 –95
-

- Mori K, Manabe T, Nii M, et al.** Plasma levels of natriuretic peptide and echocardiographic parameters in patients with Duchenne's progressive muscular dystrophy. *Pediatr Cardiol* **2002**; 23: 160–166.
- Moriuchi T, Kagawa N, Mukoyama M, et al.** Autopsy analyses of the muscular dystrophies. *Tokushima J Exp Med*. **1993**; 83 –93.
- Muntoni F, Gobbi P, Sewry C, et al.** Deletions in the 50 region of dystrophin and resulting phenotypes. *J Med Genet* **1994**;31(11):843-847.
- Muntoni F, Torelli S, Brockington M.** Muscular dystrophies due to glycosylation defects. *Neurotherapeutics* **2008**;5:627–32.
- Muntoni F.** Cardiac complications of childhood myopathies. *J Child Neurol* **2003**; 18: 191–202.



- Nakayama T, Saito Y, Uchiyama T, et al.** Pathogenesis of pulmonary thrombosis in Duchenne muscular dystrophy; a consideration from changes in serum CK and LDH levels. *Rinsho Shinkeigaku*. **2000**;40 :55 –58
- Nigro G, Comi LI, Politano L, et al.** The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. *Int J Cardiol*. **1990**;26 :271 –277
- Norman A, Harper P.** A survey of manifesting carriers of Duchenne and Becker muscular dystrophy in Wales. *Clin Genet* **1989**;36(1):31- 37.
-

O

Ogata H, Ishikawa Y, Ishikawa Y, et al. Beneficial effects of β -blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. *J Cardiol* **2009**; 53: 72–78.

Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac Troponin T levels for risk stratification in acute myocardial ischaemia. *N Engl J Med* **1996**;335:1333–41.

Ordonez-Llanos J, Santalo-Bel M, Merce-Muntanola J, et al. Risk stratification of chest pain patients by point-of-care cardiac troponin T and myoglobin measured in the emergency department, *Clin. Chim. Acta* **2006**;365: 93–97.

P

Padman R, Lawless S, Von Nessen S. Use of BiPAP by nasal mask in the treatment of respiratory insufficiency in pediatric patients: preliminary investigation. *Pediatr Pulmonol.* **1994**;17 :119 –123

Parmacek MS and John Solaro R. Biology of the Troponin Complex in Cardiac Myocytes. *Progress in Cardiovascular Disease*, **2004**, Vol. 47, No. 3: 159-176.

Penn AS, Lisak RP, Rowland LP. Muscular dystrophy in young girls. *Neurology* **1970**;20:147-159.

Politano L, Nigro V, Nigro G, et al. Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophy. *J Am Med Assoc* **1996**;275:1335-1338.

Porreca E, Guglielmi MD, Uncini A, et al. Haemostatic abnormalities, cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic patients. *Thromb Haemost.* **1999**;81 :543 –546

Prior T, Bridgeman S. Experience and strategy for the molecular testing of Duchenne muscular dystrophy. *J Mol Diagn.* **2005**;7 (3):317 –326.

Puchalski MD, Williams RV, Askovich B, et al., Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy? *Int J Cardiovasc Imaging* **2009**; 25: 57–63.

Q

Quinlivan RM, Dubowitz V. Cardiac transplantation in Becker muscular dystrophy. *Neuromuscul Disord* **1992**; 2: 165–167.


R

Ramaciotti C, Heistein LC, Coursey M, et al. Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life. *Am J Cardiol* **2006**; 98: 825–827.

Rhodes J, Margossian R, Darras BT et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. *Pediatr Cardiol* **2008**; 29: 343–351.

Ricchiuti V, Apple FS. RNA expression of cardiac troponin T isoforms in diseased human skeletal muscle. *Clin Chem* **1999**;45:2129–35.

Ricchiuti V, Apple FS. RNA expression of cardiac troponin T isoforms in diseased human skeletal muscle. *Clin Chem* **1999**;45:2129–35.



Sachdev B, Elliott PM, McKenna WJ. Cardiovascular Complications of Neuromuscular Disorders. *Curr Treat Options Cardiovasc Med* **2002**; 4: 171–179.

Saito T, Matsumura T, Miyai I, et al. Carvedilol effectiveness for left ventricular-insufficient patients with Duchenne muscular dystrophy. *Rinsho Shinkeigaku*. **2001**;41: 691–694.

Saito T, Matsumura T, Nozaki S, et al. A case of Duchenne muscular dystrophy showing coagulation cascade activation induced by muscle destruction due to convulsion. *Rinsho Shinkeigaku*. **2003**;43 :274 –276

- Sasaki K, Sakata K, Kachi E, et al.** Sequential changes in cardiac structure and function in patients with Duchenne type muscular dystrophy: a two-dimensional echocardiographic study. *Am Heart J.* **1998**;135 :937 –944.
- Schoeffler, M. et al.** Increased troponin I level in a Duchenne muscular dystrophy patient with normal coronarography. *Annales francaises danesthesie et de reanimation* **2008**; 27, 345-347.
- Selcen D.** Myofibrillar myopathies. *Curr Opin Neurol* **2008**;21:585–9.
- Sewry CA, Sansome A, Clerk A, et al.** Manifesting carriers of Xp21 muscular dystrophy; lack of correlation between dystrophin expression and clinical weakness. *Neuromusc Disord* **1993**;3(2):141-148.
- Shaddey RE, Tani LY, Gidding SS, et al.** B-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. *J Heart Lung Transplant.* **1999**;18 :269 –274
- Sharma S, Jackson PG, and Makan J.** Cardiac troponins *Clin Pathol.* **2004**; 57(10): 1025–1026.
- Shave R , Dawson E, Whyte G, et al.** The cardiospecificity of third-generation troponin T assay after exercise-induced muscle damage. *Med Sci Sports Exerc* **2002**;34:651–4.
-

- Silva MC, Meira ZM, Gurgel Giannetti J, et al.** Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. *J Am Coll Cardiol* **2007**; 49: 1874–1879.
- Silversides CK, Webb GD, Harris VA, et al.** Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. *Am J Cardiol.* **2003**; 91:769 – 772.
- Simonds AK, Muntoni F, Heather S, et al.** Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. *Thorax.* **1998**;53 :949 –952
- Stollberger C, Finsterer J.** Left ventricular synchronization by biventricular pacing in Becker muscular dystrophy as assessed by tissue Doppler imaging. *Heart Lung* **2005**; 34: 317–320.
- Stollberger C, Winkler-Dworak M, Blazek G, et al.** Association of electrocardiographic abnormalities with cardiac findings and neuromuscular disorders in left ventricular hypertrabeculation/non-compaction. *Cardiology* **2007**;107:374–379.
- Stubbs P, Collinson P, Moseley D, et al.** Prognostic significance of admission Troponin T concentrations in patients with myocardial infarction. *Circulation* **1996**;94:1291–7.
-

T

Thrush PT, Allen HD, Viollet L, et al. Re-examination of the electrocardiogram in boys with Duchenne muscular dystrophy and correlation with its dilated cardiomyopathy. *Am J Cardiol* **2009**; 103: 262–265.

Tietz NW. Clinical guide to laboratory tests , 3rd ed., (W.B. Saunders eds. Philadelphia USA) (**1995**), 180.

Todorova A, Todorov T, Georgieva B, et al. MLPA analysis/complete sequencing of the DMD gene in a group of Bulgarian Duchenne/Becker muscular dystrophy patients. *Neuromuscul Disord.* **2008**;18 (8):667 –670.

Towbin JA, Hejtmancik JF, Brink P, et al. Xlinked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. *Circulation* **1993**;87:1854–65.

Tsuyoshi Matsumura, Toshio Saito, Harutoshi Fujimura, et al. Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients. *Brain & Development* **2007**;29: 496–501.

U

Ueda Y, Kawai H, Adachi K, et al. Cardiac dysfunction in female gene carriers of Duchenne muscular dystrophy (Japanese). *Rinsho Shinkeigaku* **1995**;35(11):1191-1198.

Ugalde V, Walsh S, Abresch RT, et al. Respiratory abdominal muscle recruitment and chest wall motion in myotonic dystrophy. *J Appl Physiol.* **2001**;91 :395 –407.

V

Vatta M, Stetson SJ, Perez-Verdia A, et al. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. *Lancet* **2002**; 359: 936–941.

W

Wagner KR. Genetic diseases of muscle. *Neurol Clin* **2002**;20:645–678.

Wallace GQ, McNally EM. Mechanisms of Muscle Degeneration, Regeneration, and Repair in the Muscular Dystrophies. *Annu Rev Physiol* **2009**;71:37–57.

Watanabe K, Izumi T, Natsui M, et al. Dystrophin negative skeletal and myocardial muscle cells in a carrier of Duchenne's muscular dystrophy. *Eur Heart J* **1993**;14(7):989-992.

Wong BL, Christopher C. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. *J Child Neurol.* **2002**;17 :183 –190.

Y

Yoshioka M. Clinically manifesting carriers in Duchenne muscular dystrophy. *Clin Genet* **1981**;20:6-12.

Yotsukura M, Fujii K, Katayama A, et al., Nine-year follow-up study of heart rate variability in patients with Duchenne-type progressive muscular dystrophy. *Am Heart J.* **1998**;136 :289 – 296.

Z

Ziya Kaya, Katus HA, Rose NR. Cardiac troponins and autoimmunity: Their role in the pathogenesis of myocarditis and of heart failure. *Clinical Immunology* **2010**; 134(1):80-88
